2344 Likes
Thanks to our excellent speakers, we are fortunate in this issue of ESPE News to have
insights into several of the talks you will be able to enjoy at ESPE 2021 Online. On page 6, Ali Abbara and Waljit Dhillo review our
understanding of kisspeptin’s role in puberty, with exciting potential developments in its therapeutic and diagnostic use. Meanwhile, on page 7, Peter Kühnen examines the melanocortin
4 receptor (MC4R) agonist setmelanotide as a treatment option in rare obesity syndromes. He explains the capacity of MC4R agonists to activate
different downstream signalling cascades (‘biased signalling’) and therefore elicit a range of effects. Supporting transgender/gender diverse youth
remains a complex and topical area of healthcare. Stephen Rosenthal discusses the associated issues, which he will address in his forthcoming presentation (page 8).
You can find out more about ESPE 2021
Online at www.eurospe.org/espe2021online.
As always, your contributions will form a central part of the meeting, so please make sure to submit your abstracts by 10 May 2021.
On page 4, we are extremely pleased to have contributions from colleagues in India about their lives in the time of COVID. Researchers
Anuradha Khadilkar and Vandana Jain reflect on the pandemic’s impact on their work with patients and other aspects of their research and daily
lives.The rest of the issue is bursting with the opportunities and support available to you from
ESPE. These extend from grants and committee vacancies to the prospect of future events such as ESPE Schools and the postponed ESPE Science
Symposium. Read on to learn more!We thank all this issue’s contributors for writing for us at such a busy and stressful time.
We wish them, you, and all your families and friends, health and peace in the coming months.
Sarah Ehtisham
Editor, ESPE News
Sarah.Ehtisham@mediclinic.a
Follow ESPE
online…
Keep an eye on
the latest ESPE news
and activities at
www.eurospe.org
You can also follow
ESPE on Facebook
and Twitter/EuroSPE
Annual Business Meeting 2021 For the latest updates from ESPE, members are invited to join us for our Annual Business Meeting, which will be held virtually at 15.00 CEST on Monday 13 September 2021. Book your place via the link that was recently emailed to you. New Early Career Taskforce The new Early Career Paediatric Endocrinologists (ECPE) Taskforce will develop ESPE’s strategy for supporting younger colleagues. Five positions are available on the Taskforce. Apply now to get involved. Apply by 15 September 2021 See www.eurospe.org/about/vacancies Rare Disease Advisory Group This new working group will advise ESPE Council on how best to sustain our activities in the field of rare diseases, alongside other organisations worldwide. Find out more at www.eurospe.org/about/committees/ rare-disease-advisory-group
ESPE Grants There are deadlines in September for applications for two of our grants, offering funding opportunities for paediatric endocrinologists in either the early or mid-stage of their careers. Visiting Professorship of Rare Diseases Apply by 15 September 2021 See www.eurospe.org/grants-awards/grants/ visiting-professorship Early Career Scientific Development Grant Apply by 30 September 2021 See www.eurospe.org/grants-awards/grants/ early-career-scientific-development-grant
New leaflet on monogenic diabetes ’Monogenic diabetes’ is the topic of the latest ESPE patient information booklet. It is available in both easy and average readability versions. You can find all the patient booklets at www.eurospe.org/patients
Supporting this issue’s theme The category Puberty under General Content includes five chapters:
Nine problem-solving cases are also described. In addition, Puberty within Resource Limited Countries provides a chapter ‘Precocious and delayed puberty’ and three problem-solving cases, all in five languages (English, French, Spanish, Chinese and Swahili). The category Puberty in the Russian language has one chapter entitled ‘Puberty’ and a problem-solving case of precocious puberty. See www.espe-elearning.org Registration is free of charge
ESPE Connect webinars In response to your request for increased year-round educational content, we have launched ESPE Connect: a series of webinars taking place every 2 months. The webinars will maintain the high levels of scientific quality for which ESPE is renowned. ESPE Connect webinars are free for ESPE members to attend. Non-members can register for each webinar for just €25. Our next ESPE Connect webinar is: A multidisciplinary approach to Noonan syndrome Convenor: Mehul Dattani (UK) Tuesday 12 October 2021 16.00–17.30 CEST • Introduction and welcome – Mehul Dattani (UK) • Cardiac associations – Juan Pablo Kaski (UK) • Genetics of Noonan syndrome – Emma Burkitt Wright (UK) • Endocrine aspects – Bradley Miller (USA) • Panel discussion • Close discussion – Mehul Dattani (UK) Register at www.eurospe.org/education/webinar-series European Training Requirements The latest European Training Requirements in Paediatric Endocrinology & Diabetes document (ETR) was approved by the European Academy of Paediatrics, European Board of Paediatrics and Union of European Medical Specialists earlier this year. The ETR was revised by Syllabus Taskforce members Kanetee Busiah (Switzerland), Aleksandr Peet (Estonia), Gianluca Tornese (Italy) and Naomi Weintrob (Israel) under the leadership of Leena Patel (UK). Many trainees, consultants, and members of the Education and Training Committee and of ESPE Council provided valuable contributions. We recognise that each country must comply with its own professional regulatory requirements for postgraduate medical training. The ETR can be used to complement country-specific training programmes. Please put us in contact with the lead for paediatric endocrinology and diabetes training in your country via espe@eurospe.org to help disseminate the ETR effectively in your region. ETR content/syllabus tracking tool Trainees will shortly be able to download a tracking tool from the ESPE website, to help self assess their level of competence regarding the items in the syllabus, to keep a record for their portfolio and to jointly review with their trainer/educational supervisor. You can download the ETR at www.eurospe.org/education/ education-training-syllabus Reports from ESPE schools Both the ESPE Summer School and the ESPE Diabetes, Obesity & Metabolism (DOM) School took place in May. They were held virtually, due to the impact of COVID-19. Although those involved would have liked to have met in person, both schools were a great success and received very positive feedback. Read the Summer School report at https://bit.ly/SummerSchoolReport Read the DOM School report at https://bit.ly/DOMReport
This multicentre, questionnaire-based, online survey by Sarteau and colleagues assessed the changes to delivery of care to children with type 1 diabetes in nine centres across five countries (the USA, Australia, Sweden, China and India). The survey was conducted between May and August 2020, covering the immediate adaptation of these centres to the first peak of the COVID-19 pandemic. This article makes an interesting read, as the responses of these centres were quite variable in four areas: ‘clinic roles’, ‘care delivery’, ‘data collection and administrative platforms’ and ‘provider and patient concerns and challenges’. Healthcare provider concerns over increased frequency of diabetic ketoacidosis, widening disparities in resources, and challenges for patients associated with non-availability of internet/technology for telemedicine are emphasised. The survey also highlights the unanticipated ‘silver linings’ in terms of the emergence of telemedicine as ‘new best practice’, improved data sharing between patient and clinic staff, improved efficiency of consultation and adherence to routine care.
Obesity is the main cause of the current global epidemics of type 2 diabetes, hypertension, cardiovascular disease and many other disorders. A subgroup of patients with obesity shows preserved insulin sensitivity, normal blood pressure and a beneficial lipid profile. These individuals are often referred to as having ‘metabolically healthy obesity’ (MHO). MHO is controversially discussed as either a stable phenotype or a transitional state that progresses to metabolic dysfunction (metabolically unhealthy obesity). Zhou et al. examined data from 381 363 probands from the UK Biobank and determined the association of MHO, as well as its transition, with all-cause mortality, diabetes, atherosclerotic cardiovascular disease, heart failure and respiratory diseases. They found that people with MHO had higher incidents of heart failure and respiratory disease, but not higher rates of atherosclerotic cardiovascular disease, compared with people who were not obese. The authors conclude that weight management should be recommended to all people with obesity, irrespective of their metabolic status.
Type 1 diabetes is associated with a degree of cognitive decline and smaller cortical volume. Hypoglycaemia is thought to play a role, especially severe hypoglycaemic episodes. Stantonyonge and coworkers investigated the effects of impaired hypoglycaemia awareness (IHA) amongst a cohort of 40 patients with type 1 diabetes, half of whom had IHA. The subjects underwent magnetic resonance imaging (MRI) studies for grey and white matter changes. The patients with IHA had significantly reduced grey matter volumes and cortical surface areas, particularly in the frontal and parietal regions and in the white matter tracts. The differences seen correlated with severity of IHA and with the frequency of severe hypoglycaemia. Whilst further studies are needed to establish causality, the MRI data are concerning. The implication is that IHA increases the risk of severe hypoglycaemia and further increases the risk of grey and white matter changes in the brain
LUM-201 is an oral growth hormone (GH) secretagogue that acts by stimulating the GHSR1 receptor in the hypothalamus and pituitary. Bright et al. conducted a randomised, placebo controlled, multicentre study in 68 prepubertal children with an established diagnosis of GH deficiency, who had never been treated before. The aim was to determine predictive enrichment markers (PEMs) for subjects who would respond to LUM-201. LUM-201 (ibutamoren) was administered in single daily oral doses of 0.4mg/kg (n=22) or 0.8mg/kg (n=24). Sensitivity, specificity and accuracy of potential markers to predict 6-month growth responses to LUM-201 and recombinant human GH were analysed. The PEMs identified for a favourable growth response to LUM-201 were a baseline insulin-like growth factor-1 concentration >30ng/dl and a peak GH response ≥5ng/ml upon administration of a single dose of LUM-201. Further studies to determine if the predictive accuracy is maintained for a longer duration of treatment are required
Polycystic ovary syndrome (PCOS) is the most frequent cause of hirsutism and menstrual irregularity in adolescent girls and young women, and its prevalence is rising worldwide.1,2 The condition is accompanied by long term co-morbidities (including subfertility and diabetes) that affect lifetime well-being, and result in a burden on healthcare systems. The outcome of a mismatch PCOS in adolescent girls is commonly driven by ectopic lipid accumulation (mainly in the liver and viscera) resulting from a mismatch between (reduced) prenatal weight gain and (augmented) postnatal weight gain: in other words, between early adipogenesis and later lipogenesis, or between the capacity for lipid storage and the subsequent demand for it.1,3 PCOS is thus the outcome of a chronic need to store more fat than is safely feasible in subcutaneous white adipose tissue (WAT).
Genetic variants that control appetite may contribute to such a mismatch, along with an unhealthy lifestyle and a low activity of brown adipose tissue (BAT).1,3 Ectopic fat accumulation is accompanied by insulin resistance, luteinising hormone hypersecretion, and low concentrations of circulating high molecular weight (HMW) adiponectin, an adipokine with insulin-sensitising and anti inflammatory properties.1,3 Treatment: let’s reduce ectopic fat There is no approved therapy for PCOS in adolescent girls and young women. The traditional approach is to focus on obvious symptoms such as hirsutism, acne/seborrhoea and
irregular menses. Accordingly, oral contraceptives (OCs) are prescribed to the vast majority of young PCOS patients, including to girls who are not sexually active.1 OCs mask the problem, but do not solve it. They attenuate key symptoms, but do not revert the underlying pathophysiology, so that young patients with PCOS remain at risk for co-morbidities and for post-treatment rebounds. Given the key role of ectopic fat excess in the development of PCOS, the prime aim of the treatment should be a preferential loss of ectopic or central fat. This can be achieved with sustained lifestyle measures that combine regular exercise with a healthy diet and with respect for biorhythm and sleep.4 Pharmacological options If these lifestyle measures fail, then a pharmacological addition can be helpful.
In young PCOS patients with obesity, future studies with glucagon-like peptide-1 agonists will disclose their potential to elicit a loss of body weight and, in particular, a loss of central fat. In young PCOS patients without obesity, limited data suggest that combinations of time-honoured generics (acting through different pathways) can reduce ectopic fat without necessarily lowering body weight. So far, the most promising results may be those obtained with SPIOMET, which is a low dose combination of: • spironolactone (50mg/day), to antagonise androgen and mineralocorticoid effects, and to activate BAT • pioglitazone (7.5mg/day), to increase WAT adipogenesis and to raise HMW adiponectinaemia, without increasing body weight, and • metformin (850mg/day), to augment insulin sensitivity and to reduce appetite and liver fat, possibly via growth and differentiation factor 15 (GDF15),5 which acts through a specific receptor in the brainstem.
The effects of SPIOMET versus those of an OC (containing ethinyloestradiol–levonorgestrel) have been investigated in two randomised, open-label, single-centre pilot studies performed in non-obese adolescents with PCOS who did not need contraception. The pooled results showed that SPIOMET had more normalising effects than the OC, notably on hepatic and visceral fat, on insulin sensitivity, and on post-treatment ovulation rate (Figure).6,7 In the coming years, the efficacy and safety of SPIOMET (in a single tablet) on top of lifestyle intervention will be investigated. This large, double-blind, multicentre, EU-funded trial is part of a paediatric investigation plan approved by the European Medicines Agency. Stay tuned! Lourdes Ibáñez University of Barcelona, Spain Francis de Zegher University of Leuven, Belgium
Ana Claudia Latronico’s research has examined genotype– phenotype correlations in central precocious puberty caused by MKRN3 mutations.
Makorin RING finger 3 (MKRN3) is an intronless gene located inside a region containing an imprinted gene cluster at chromosome 15q11-q13. MKRN3 loss-of-function mutations represent the most common genetic cause of familial central precocious puberty (CPP).1,2 Different types of mutations (frameshift, stop gain, missense) affecting the MKRN3 protein or the gene promoter region have been described in recent years.1 Recently, my research group at São Paulo University, in collaboration with international paediatric groups, described the genotypic and phenotypic features of a large cohort (Latin American, North American, European, Israeli and Turkish subjects) of patients with CPP due to deleterious defects of MKRN3. 2 This multiethnic cohort comprised 71 patients (from 36 unrelated families) with CPP caused by 18 MKRN3-inactivating mutations. Clinical characteristics Both female and male patients carrying MKRN3 mutations exhibited typical clinical and biochemical features of premature reactivation of the reproductive axis. Girls started pubertal development at a mean age of 6.2±1.2 years, whereas in boys it was at 7.1±1.5 years. We demonstrated higher levels of basal follicle-stimulating hormone (FSH) and an earlier age at diagnosis in girls with CPP associated with MKRN3 defects when compared with an idiopathic CPP group. The shorter interval between initial manifestations and diagnosis of CPP in patients with MKRN3 mutations was probably related to the fact that 51% of them had a familial history of precocious puberty, increasing the awareness of parents and doctors for premature sexual development in a second case in the same family. Notably, 87.5% of all male patients with MKRN3 mutations from this latest study were diagnosed through familial screening; only a few boys were index cases (5 out of 36 index cases). Some of these affected boys were under-diagnosed in childhood and the CPP history was only recognised retrospectively in adult life, while others were siblings of index patients and had an earlier diagnosis that might have been undetected otherwise. Therefore, we believe that male CPP caused by MKRN3 mutations can be clinically subtle. Genetic analysis To date, all described patients with MKRN3 loss-of-function mutations have a paternal origin when familial segregation analysis was possible. A documented de novo MKRN3 mutation has not been described to date, indicating that true sporadic cases are very uncommon. Among the 18 rare inactivating mutations in the MKRN3 gene, one was nonsense, six were frameshifts, and 10 were missense mutations, along with a promoter region deletion. A recurrent frameshift mutation (p.Pro161Argfs*) wa
identified in 46% of the patients with CPP, confirming this site as a hotspot region. Severe MKRN3 mutations, such as stop gain and frameshift mutations, were associated with greater bone age advancement and higher basal luteinising hormone (LH) levels, suggesting that these mutations could lead to a prolonged or greater impact of oestradiol levels on bone maturation or more rapid advancement of puberty. Disease mechanisms Based on in silico protein analysis and in vitro studies, we demonstrated that missense variants affecting MKRN3 could lead to precocious puberty by at least two hypothetical mechanisms: (1) destabilising the protein and generating reduced inhibition of genes that promote puberty, and (2) affecting critical regions (i.e. RING fingers) that are relevant to ubiquitination and overall MKRN3 repressor activity.3,4 Other rarer mechanisms are deletions in the 5′ untranslated regulatory region or even of the entire gene.4 A high prevalence of overweight and obesity was observed in CPP patients with or without MKRN3 mutations (47.3% and 50% respectively), followed by a significant reduction after gonadotrophin-releasing hormone (GnRH) analogue treatment.2,5 Mean final height was similar in CPP groups with or without MKRN3 mutations when treated with GnRH analogues, indicating adequate response to this treatment in both groups.5 In conclusion Our study demonstrated that the premature sexual development phenotype caused by MKRN3 loss-of-function mutations is indistinct from idiopathic CPP. However, collectively, a shorter time to presentation and higher FSH levels were found in the patients with CPP due to MKRN3 mutations. Notably, severe MKRN3 defects can have a greater impact on phenotype (greater bone age and high basal LH levels) when compared with pathogenic missense variants. Ana Claudia Latronico São Paulo University, São Paulo, Brazil
Margaret Zacharin explores the issues and sensitivity involved in supporting families with additional needs, in the context of puberty
So, it’s Monday morning. You’re on the way to outpatients, looking forward to a few TSH 7.5mU/l’s, maybe a constitutional delay and, if you’re lucky, a well-controlled CAH. The first family appears: an exhausted mother, wheeling a double pram with a clearly developmentally delayed 8-year-old girl with a long leg plaster, plus her brother, thrashing around irritably next to her. They are accompanied by a 14-year-old agitated young woman, clasping her mother’s arm. This morning’s clinic is not looking to be as simple as you might have imagined! A brief history ascertains that the older girl has severe autism, and is currently under the care of developmental paediatrics and psychiatry. She achieved menarche 3 months ago. Enormous family and social difficulties become apparent in your history-taking: the girl having escalating anxiety at the sight of menstrual blood, demonstrating grossly disinhibited behaviours and tantrums, throwing away her menstrual pads in public. The other children are twins, born at 24 weeks gestation, with the unfortunate consequences of extremely preterm birth, both with cerebral palsy. The little boy is agitated but more mobile than his sister. He is intermittently quite aggressive, recently having sat on his severely disabled sister, breaking her femur. Further history-taking ascertains that this is a single parent family, father having departed, struggling financially and socially, with major issues with school and carers. To make matters worse, the 8-year-old is showing distinct signs of breast development over 9 months, with increased irritable episodic screaming for no apparent reason. Mother has major fears that she will follow her sister’s pattern after menarche
How on earth are you going to manage this family? Being an endocrinologist, you haven’t thought a lot about developmental problems and their consequences for quite some time and your gynaecology was always a bit scratchy. After taking a deep breath, you remember to ascertain that the little girl is non-verbal, gastrostomy fed, with difficult epilepsy, requiring four anticonvulsants. Pubic hair has been present from age four. Mother’s concerns relate to puberty and whether she will manage! Her brother is smaller, as second twin, his birth weight 550 grams at 24 weeks. Fortunately, despite chronic lung problems, his epilepsy is less severe. Behavioural disturbance has significantly worsened since father departed, throwing household items and recently injuring his sister. Looking after these children, the mother is distraught, particularly with the older girl reacting so badly, with increased behavioural disturbance preceding and during menstruation. School has reported worrying, risky, sexualised interactions with boys at special school. By this time you’re feeling as desperate as the mother. Clearly, advice and management will require complex interdisciplinary care, but much will devolve to you, to formulate a plan to make this family’s life tolerable. To first deal with the older girl seems sensible, then perhaps a staff member can help while you discuss options for the twins. She reacts wildly when she sees blood, a common issue with autism. Stopping periods with a continuous contraceptive pill seems an option, but occasional respite care, visiting her father, risks erratic medication delivery, consequent withdrawal bleeds and exacerbated problems! The implantable progestogen rod is clearly inappropriate, with 10% likelihood of amenorrhoea and requiring general anaesthesia for insertion. A progesterone-bearing IUD might solve the dilemma, being low dose without hypothalamic-pituitary gonadal (HPG) axis inhibition, whilst providing 4−5 years of amenorrhoea and complete contraception. Mother was unaware of this possibility for a young teenager and is absolutely delighted to hear that gynaecologic referral may significantly alter the burden of care for her daughter. You breathe a sigh of relief as you appear to have gained the mother’s trust. You cautiously move to the 8-year-old, with a minimal trauma long bone fracture, at risk for more. When you examine her, she is 145cm with stage 3 breast and stage 4 pubic hair. A long explanation of various management options will confuse mother. You start with a GnRH agonist, but mother is worried; she just wants periods prevented and is not at all interested in maximised height. Two similar menstrual disasters would be impossible! Repeated specialist visits would create a further burden, so you suggest depot progestogen to effectively prevent menstruation and slow pubertal progress. This sounds better, as the local doctor can administer 3-monthly injections. You remember to say that, whilst this treatment is good at age eight, under no circumstances can it continue beyond age 12 without addition of oestrogen, because it inhibits the HPG axis with failure of bone mass accrual. Eventually, an IUD like her sister will be possible, after completion of uterine growth. Mother interrupts to ask about possible further fractures. The conversation is complicated. You explain that whilst anticonvulsants and immobility reduce bone quality, sex hormone accumulates cortical thickness, with
ESPE 2021 Online is ESPE’s virtual Annual Meeting, providing you with the
latest developments in paediatric endocrinology.
22−26 September 2021
‘The theme of ‘Lifelong endocrine care through collaboration, discovery and innovation’ lays the perfect
foundation for the inspiring scientific programme. Our online platform will allow you to plan and schedule
the sessions that interest you most, whilst offering plenty of opportunities for you to connect with peers and
speakers around the world to discuss the rich and stimulating content.
Sessions led by world-renowned speakers will be available on demand following their initial broadcast,
allowing you to access more information than ever before!
Register today to save up to 30% on registration fees for ESPE 2021 Online. The standard registration fees are only available until Tuesday 7 September (23.59 BST), after which increased fees apply. Standard registration deadline 7 September 2021 (23.59 BST) For further information see www.eurospe.org/ espe2021online/ registration
[contact-form-7 id="520" title="Comments"]